-
Duke University gets $3.9M grant for ACL research
Durham, N.C.-based Duke University has won a $3.9 million grant to study gender differences in ACL injuries, according to a Dec. 20 report from WRAL News. -
Atreon Orthopedics hits 10,000 cases with shoulder biologic
Columbus, Ohio-based Atreon Orthopedics has completed 10,000 rotator cuff repair surgeries with the use of its Rotium bioresorbable wick. -
RTI Surgical rebrands to Evergen
RTI Surgical, a contract development and manufacturing organization for regenerative medicine, rebranded to Evergen. -
Neural stem cell transplant could address chronic spinal cord injuries
A clinical trial out of the University of California San Diego School of Medicine found that neural stem cell transplantation had shown long-term safety and feasibility for treating chronic spinal cord injuries. -
Theradaptive earns additional FDA OK for OsteoAdapt spine study
Theradaptive earned the FDA's investigational device exemption approval to broaden its clinical research for the OsteoAdapt SP implant, the company said Dec. 10. -
Spine biologic procedure found safe and effective in 3-year study
Three-year data for the Discseel spine procedure found it was effective and could replace most spine surgeries, Discseel Technologies said Dec. 4. -
Bioretec pushes RemeOs screw into the US market
Bioretec signed a distribution agreement to accelerate commercialization of the RemeOs trauma screw system in the U.S., according to a Nov. 22 news release. -
6 recent orthobiologics updates
From company acquisitions to FDA nods, here are six key updates in orthobiologics since Oct. 4. -
Acuitive Technologies earns FDA clearance for new bone void filler
Acuitive Technologies earned FDA clearance for the Citrepore bioactive bone filler, the company said Nov. 12. -
Theradaptive's OsteoAdaptSP safety, efficacy supported in study: 5 notes
Biologics company Theradaptive's lead therapeutic, OsteoAdapt SP, has been featured in a preclinical spinal fusion study published in Spine, a prominent, peer-reviewed publication for spinal surgeons. -
The challenge ahead for spine biologics
Spine biologics holds incredible potential if it can overcome obstacles related to disc anatomy, Ezriel Kornel, MD, said. -
CytexOrtho earns FDA approval for absorbable hip implant trials
CytexOrtho has earned FDA approval to begin a clinical trial evaluating the safety and efficacy of its absorbable hip implant in human patients, according to an Oct. 29 report from Mass Device. -
Regenerative Orthopedics & Sports Medicine partners on rotator cuff research
Washington, D.C.-based Regenerative Orthopedics & Sports Medicine has partnered with the Orthobiologics Research Initiative to support nonsurgical orthopedic research aimed at treating partial-thickness rotator cuff tears using cutting-edge orthobiologic procedures. -
Full Circle Orthopedics expands regenerative medicine services
Phoenix-based Full Circle Orthopedics is expanding its regenerative medicine program, according to an Oct. 22 news release. -
11 places adding the BEAR implant since 2023
Since the start of 2023, several practices and health systems have added the Bridge-Enhanced ACL restoration procedure, which uses a patient's blood to help heal the injury. -
Bone Biologics adds to board of directors
Bone Biologics appointed Phillip Meikle to its board of directors, according to an Oct. 21 news release. -
Spine patient sues over tainted bone graft: 5 notes
A woman is suing Elutia, formerly Aziyo Biologics, after contracting tuberculosis from a product used in an April 2021 spine surgery, The Atlanta Journal-Constitution reported Oct. 17. -
Tetrous earns patent for bone fiber implants
Tetrous, a start-up focused on bone-to-tendon healing following orthopedic surgery, has earned a fourth patent related to its EnFix family of demineralized cortical bone fiber implants. -
5 spine, orthopedic biologic companies to know
Here are five spine and orthopedic companies that specialize in regenerative medicine and biologic implants. -
Regenity Biosciences earns FDA clearance for knee implant
Regenity Biosciences earned FDA 510(k) clearance for RejuvaKnee, a collagen-based meniscus implant designed for reinforcement and repair of soft tissue injuries of the meniscus, the company said Oct. 8.
Page 1 of 37